Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.260
-0.050 (-3.82%)
At close: May 9, 2025, 4:00 PM
1.300
+0.040 (3.17%)
After-hours: May 9, 2025, 7:27 PM EDT
Aclaris Therapeutics Employees
As of December 31, 2024, Aclaris Therapeutics had 64 total employees, including 61 full-time and 3 part-time employees. The number of employees decreased by 27 or -29.67% compared to the previous year.
Employees
64
Change (1Y)
-27
Growth (1Y)
-29.67%
Revenue / Employee
$277,766
Profits / Employee
-$2,034,516
Market Cap
136.43M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
ACRS News
- 1 day ago - Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewsWire
- 2 days ago - Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 days ago - Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewsWire
- 3 months ago - New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewsWire
- 4 months ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga